Skip to main content
SpringerLink
Log in

The Role of Anatomic and Functional Imaging in Myeloma

  • Chapter
Myeloma Therapy

Part of the book series: Contemporary Hematology ((CH))

  • 512 Accesses

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Durie BGM, Kyle RA, et al. Myeloma management guidelines: a consensus report from the Scientific Advisors of the International Myeloma Foundation. Hematol J. 2003; 4: 379–98.

    Article  PubMed  Google Scholar 

  2. Durie BGM, Jacobson J, et al. Magnitude of response with myeloma frontline therapy does not predict outcome: importance of time to progression in Southwest Oncology Group chemotherapy trials. J Clin Oncol. 2004; 22(10): 1857–63.

    Article  PubMed  Google Scholar 

  3. Durie BGM, Salmon SE. A clinical staging system for multiple myeloma. Cancer 1975; 36: 842–854.

    Article  PubMed  CAS  Google Scholar 

  4. Gahrton G, Durie BGM, et al. Multiple Myeloma and Related Disorders, The role of imaging in myeloma. Arnold 2004; 10: 155–63.

    Google Scholar 

  5. Greipp PR, Durie BGM, et al. International sStaging sSystem for multiple myeloma. J Clin Oncol. 2005; 23(15): 3412–20.

    Article  PubMed  Google Scholar 

  6. Kyle RA, Schreiman JS, et al. Computer tomography in diagnosis and management of multiple myeloma and its variants. Arch Intern Med. 1985; 145: 1451–2.

    Article  PubMed  CAS  Google Scholar 

  7. Antoch G, Vogt FM, Freudenberg LS, et al. Whole-body dual-modality PET/CT and whole-body MRI for tumor staging in oncology. JAMA 2003; 290: 3199–206.

    Article  PubMed  CAS  Google Scholar 

  8. Modic MT, Obuchowski N. Whole-body CT screening for cancer and coronary disease: does it pass the test? Cleveland Clin J Med 2004; 71(1): 47–56.

    Article  Google Scholar 

  9. Durie BGM, Waxman AD, et al. Whole Body F-FDG PET identifies high-risk myeloma. J Nucl Med. 2002; 43: 1457–63.

    PubMed  Google Scholar 

  10. Bauer A, Stabler A, et al. Magnetic resonance imaging as a supplement for the clinical staging system of Durie and Salmon? Cancer. 2002; 95(6): 1334–5.

    Article  Google Scholar 

  11. Walker R, Jones-Jackson L, et al. Diagnostic imaging of multiple myeloma-–FDG PET and MRI complementary for tracking short vs long term tumor response [abstract #758]. Blood. 2004; 104(11): 217a.

    Google Scholar 

  12. Kusumoto S, Jinnai I, Itoh K, et al. Magnetic resonance imaging patterns in patients with multiple myeloma. Br J of Haematol. 1997; 99: 649–655.

    Article  CAS  Google Scholar 

  13. Mariette X, Zagdanski AM, Guermazi A, et al. Prognostic value of vertebral sessions detected by magnetic resonance imaging in patients with stage I multiple myeloma. Br J of Haematol. 1999; 104: 723–729.

    Article  CAS  Google Scholar 

  14. Walker R, Barlogie B, et al. Prospective evaluation of 460 patients from total therapy II - —identification of characteristics on baseline MRI examinations of prognostic significance - —importance of focal lesions (FL) in multiple myeloma (MM). Hematol J. 2003; 4: S171. Abstract 188.

    Article  Google Scholar 

  15. Schirmeister H, Bommer M, et al. Initial results in the assessment of multiple myeloma using 18 F-FDG PET. Eur J Nucl Med. 2002; 29: 361–6.

    Article  Google Scholar 

  16. Walker RC, Barlogie B, Shaughnessy J. DKK1 in myeloma: correlation with FDG-PET. New Engl J Med. 2004; 350(14): 1465–6.

    CAS  Google Scholar 

  17. Miceli M, Atoui R, Walker R, et al. Diagnosis of deep septic thrombophlebitis in cancer patients by fluorine-18 flurodeoxyglucose positron emission tomography scanning: a preliminary report. J Clin Oncol. 2004; 22(10): 1949–56.

    Article  PubMed  Google Scholar 

  18. Mileshkin L, Blum R, Seymour JF, et al. A comparison of fluorine-18 fluoro-deox-yglucose PET and technetium-99m sestamibi in assessing patients with multiple myeloma. Europ J Haematol. 2004; 72(1): 32–7.

    Article  CAS  Google Scholar 

  19. Fonti R, Vecchio S, Zannetti A, et al. Functional imaging of multidrug resistant pheno-type by 99mTcMIBI scan in patients with multiple myeloma. 2004; 19(2): 165–70.

    CAS  Google Scholar 

  20. Durie BGM, et al. Technetium-99m-MIBI scanning in multiple myeloma (MM): comparison with PET (FDG) imaging. Blood 1996; 88: 10. Abstract 1559.

    Google Scholar 

  21. Tirovola EB, Biassoni L, Britton KE, et al. The use of 99mTc-MIBI scanning in multiple myeloma. Br J Cancer. 1996; 74: 1815–20.

    Article  PubMed  CAS  Google Scholar 

  22. Durie BGM, Waxman AD, D'Agnolo A. A whole-body Tc-99m-MIBI scanning in the evaluation of multiple myeloma (MM). J Nucl Med. 1998; 39: 138.

    Google Scholar 

  23. Jaksic W, Trudel S, Chang H, et al. Clinical outcomes in t(4;14) multiple myeloma: a chemotherapy-sensitive disease characterized by rapid relapse and alkylating agent resistance. J Clin Oncol. 2005; 23(28): 7069–73.

    Article  PubMed  CAS  Google Scholar 

  24. Dewald GW, Therneau T, et al. Relationship of patient survival and chromosome anomalies detected in metaphase and/or interphase cells at diagnosis of myeloma. Blood. 2005; 106(10): 3553–8.

    Article  PubMed  CAS  Google Scholar 

  25. Terpos E, Szydlo R, Apperley JF, et al. Soluble receptor activator of nuclear factor kB ligand-osteoprotegerin ratio predicts survival in multiple myeloma: proposal for a novel prognostic index. Blood. 2003; 102(3): 1064–9.

    Article  PubMed  CAS  Google Scholar 

  26. Chim CS, Ooi GC, et al. Unusual presentations of hematologic malignancies: role of MRI and FDG-PET in evaluation of solitary plasmacytoma. J Clinic Oncol. 2004; 22(7): 1328–30.

    Article  CAS  Google Scholar 

  27. Durie BGM. The roll of anatomic and functional staging in myeloma: Description description of Durie/Salmon plus staging system. European J of Cancer. 2006; 42:1539–43.

    Article  Google Scholar 

  28. Hillner BE, et al. Clinical decisions associated with positron emission tomography in a prospective cohort of patients with suspected or known cancer at one United States center. J Clinic Oncol. 2004; 22(20):4147–56.

    Article  Google Scholar 

  29. Walker R, Barlogie B, et al. Magnetic resonance imaging in multiple myeloma: Diagnostic diagnostic and clinical implications. J Clinic Oncol. 25(9):1121–28.

    Google Scholar 

  30. Thomsen HS. Nephrogenic systemic fibrosis: A serious late adverse reaction to gadodiamide. Eur Radiol. 2006; 16:2619–2621.

    Article  PubMed  Google Scholar 

  31. Moran GR, Pekar J, Bartolini M, et al. An Investigation of the toxicity of gadolinium based MRI contrast agents. Proc Intl Soc Mag Reson Med. 2002. 10.

    Google Scholar 

  32. Swaminathan S, Horn T, Pellowski, et al. Nephrogenic systemic fibrosis, gadolinium, and iron mobilization. N Engl J Med. 2007; 357(7): 720–722.

    Article  PubMed  CAS  Google Scholar 

  33. Hillner BE, Siegel BA, Liu D, et al. Impact of positron emission tomography/computed tomography and positron emission tomography (PET) alone on expected management of patients with cancer: Initial results from the national oncologic PET registry. J Clin Onco. 2008; 26(13). (Published ahead of print.)

    Article  Google Scholar 

  34. Salaun P-Y, Gastinne T, Frampas E, et al. FDG-positron-emission tomography for staging and therapeutic assessment in patients with plasmacytoma. Haematologica. 2008; 93(8):1269–1271.

    Article  PubMed  Google Scholar 

  35. Patel RR, Subramaniam RM, Mandrekar JN. Occult malignancy in patients with suspected paraneoplastic neurologic syndromes: value of positron emission tomography in diagnosis. Mayo Clin Proc. 2008; 83(8):917–922.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, Division of Hematology/Oncology, Cedars-Sinai Comprehensive Cancer Center, Los Angeles, CA, USA

    Brian G.M. Durie

Authors
  1. Brian G.M. Durie
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Winship Cancer Institute, Emory University, B3307 Clifton Road, Atlanta, GA, 30322, USA

    Sagar Lonial MD

Rights and permissions

Reprints and permissions

Copyright information

© 2008 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Durie, B.G. (2008). The Role of Anatomic and Functional Imaging in Myeloma. In: Lonial, S. (eds) Myeloma Therapy. Contemporary Hematology. Humana Press. https://doi.org/10.1007/978-1-59745-564-0_30

Download citation

  • DOI: https://doi.org/10.1007/978-1-59745-564-0_30

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-934115-82-4

  • Online ISBN: 978-1-59745-564-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation